The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Chimerix
Stock and Other Ownership Interests - Chimerix
Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.
 
Yazmin Odia
Consulting or Advisory Role - Abbvie; GammaTile
Research Funding - Bristol-Myers Squibb (Inst); Novocure (Inst)
Travel, Accommodations, Expenses - Novocure
 
Ashley Love Sumrall
Stock and Other Ownership Interests - Novocure (I)
Honoraria - Cardinal Health; Gerson Lehrman Group
Consulting or Advisory Role - Abbvie; Amgen; Athenex; Bayer; Merck; Novocure
Speakers' Bureau - Abbvie; Bayer; Bristol-Myers Squibb; Novocure; Prime Oncology
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Kura Oncology (Inst); Novocure (Inst); Oncoceutics (Inst)
Travel, Accommodations, Expenses - American Association of Neurological Surgeons; Bristol-Myers Squibb; Novocure; Xcenda
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research
 
Phioanh Leia Leia Nghiemphu
Consulting or Advisory Role - Abbvie
Research Funding - Novartis
 
Matthew David Hall
Honoraria - Accuray
 
Doured Daghistani
No Relationships to Disclose
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Consulting or Advisory Role - Karyopharm Therapeutics; Mevion Medical Systems; Sapience Therapeutics; Tocagen; ZappRx
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
(OPTIONAL) Uncompensated Relationships - ViewRay; Xcision Medical Systems
 
Andrew B. Lassman
Honoraria - Abbott Molecular
Consulting or Advisory Role - Bayer; BioClinica; Elsevier; FORMA Therapeutics; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; QED Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); RTOG Foundation (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Abbott Molecular; AbbVie; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Novartis; Orbus Therapeutics; Pfizer; QED Therapeutics
 
Isabel Arrillaga-Romany
Honoraria - Merck
Consulting or Advisory Role - Agios; Boehringer Ingelheim; FORMA Therapeutics; Insys Therapeutics; Karus Therapeutics
Research Funding - Astex Pharmaceuticals
 
Sharon L. Gardner
No Relationships to Disclose
 
Rohinton Tarapore
No Relationships to Disclose
 
Guangrong Lu
Employment - Oncoceutics
Stock and Other Ownership Interests - Chimerix
 
Joshua E. Allen
Employment - Chimerix; Oncoceutics
Leadership - Chimerix; Oncoceutics
Stock and Other Ownership Interests - Chimerix; Chimerix; Oncoceutics; Oncoceutics
Patents, Royalties, Other Intellectual Property - ONC201-related patents; ONC201-related patents
Travel, Accommodations, Expenses - Oncoceutics; Oncoceutics; Oncoceutics; Oncoceutics; Oncoceutics
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)